Navigation Links
Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
Date:2/9/2011

tion of Diabetic Retinopathy (DR), a disease affecting the blood vessels of the retina.  Clinically significant DME is a leading cause of blindness in younger adults (under 50).  Clinically significant DME occurs when fluid leaks into the center of the macula, the light-sensitive part of the retina responsible for sharp, direct vision.  Fluid in the macula can cause severe vision loss or blindness.

Approximately 370,000 Americans currently suffer from clinically significant DME, with 95,000 new cases arising each year.  According to the American Diabetes Association, more than 18 million Americans currently suffer from diabetes, and many other people are at risk for developing diabetes.  With the incidence of diabetes steadily climbing, it is projected that up to 10 percent of all patients with diabetes will develop DME during their lifetime.

About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com.

Regeneron Forward Looking StatementThis news release includes forward-looking statement
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Regeneron Announces Presentation at the ISI Annual Conference
2. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
3. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
4. Christine A. Poon Elected to Regeneron Board of Directors
5. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
6. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
7. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
8. Regeneron Increases Size of Public Offering of Common Stock
9. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
10. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
11. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015 IRIDEX Corporation (NASDAQ: IRIX ) ... 2015 financial results after the market closes on ... release, the Company will host a conference call with ... on Thursday, August 6, 2015 to ... developments. Interested parties may access the live ...
(Date:7/30/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... the t:slim® and t:flex™ Insulin Pumps, today announced ... with Dexcom, Inc. to allow the integration of ... G5 and G6 continuous glucose monitoring ("CGM") systems. ... with Dexcom,s future CGM systems is an important ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
Breaking Medicine Technology:IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
(Date:7/30/2015)... ... July 30, 2015 , ... " DevExpress ... takes a look at small, medium, and large businesses making an impact in ... the business review and shared with viewers how DevExpress has provided software development ...
(Date:7/30/2015)... ... July 30, 2015 , ... ... annual Institute Scholar Program. In partnership with Patient Experience Institute, these offerings reinforce ... leaders on the front lines and throughout the experience movement, and provide information ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... today that the latest issue of Inclusive™ magazine, its multimedia publication focused on ... digital edition of the new issue, Volume 6, Issue 2, as well as ...
(Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
(Date:7/30/2015)... ... 2015 , ... The New Jersey Innovation Institute (NJII), acting ... Health, has received a $2.9 million grant from the Office of the National ... and Human Services (HHS). NJII will help the Department of Health ensure the ...
Breaking Medicine News(10 mins):Health News:Software to Develop High-Performance Data-Driven Apps was Featured on NewsWatch Television 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2015 Patient Experience Grant and Scholar Programs 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 2Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 3Health News:Glidewell Laboratories Puts Out Latest Issue of Dental Implant Magazine Inclusive™ 4Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2
... a new way of administration of drug that treats ... forcefully" eases severe headaches without side effects. ,Dr. ... his study, which included 85 patients who had experienced ... 100milligrams of valproate sodium every 5 minutes until their ...
... with heart disease are more likely to have severe symptoms ... monthly menstrual cycle, according to new research from England. ... which occurs when there is insufficient oxygen supply to the ... of heart disease. Researchers from the Cardiothoracic Centre report in ...
... health, especially to the heart.Improvements in heart disease risk ... known that smoking increases the risk of heart disease. ... which raises cholesterol levels, white blood cell counts and ... in carbon monoxide levels raises the risk of tobacco-related ...
... that mothers who breast-feed their children for less than ... full intellectual potential. ,The results of intelligence tests ... those who had breast milk for less than three ... breast-fed for at least six months. However, no difference ...
... a study on the agnus castus fruit, also known ... women who took it had a 50 per cent ... ,Agnus castus (Vitex agnus castus) is a small ... has been used for ailments including haemorrhage, fevers ...
... says that certain over-the-counter pain killers should carry ... miscarriage. ,The comments follow a study by ... in this week's British Medical Journal which studied ... anti-inflammatory drugs like indomethacin (ibuprofen). ,Researchers used ...
Cached Medicine News:
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: